Has Leorah Freeman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $400,654 in general payments to Leorah Freeman, MD across 449 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leorah Freeman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leorah Freeman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leorah Freeman, MD

Neurology · Houston, TXNPI 1023463114

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $287,907 of the $400,654 with a category attached, or 71.9%. It is spread thinly across 16 manufacturers, the largest accounting for just 19.6%. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$400,654in general payments, 2019–2025

Across 449 payments — averaging $892.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

EMD Serono, Inc.$79K
Genentech USA, Inc.$59K
Bristol Myers Squibb$56K
Sanofi$53K
F. Hoffmann-la Roche AG$32K
Merck Kgaa$22K
plus $100K from 10 others

$1,157,508in research payments, 2019–2025

Across 38 payments — averaging $30,461 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

EMD Serono, Inc.$671K
Genentech, Inc.$446K
TG Therapeutics, Inc.$32K
Novartis$6K
F. Hoffmann-la Roche AG$3K

What the payments were for

Consulting fees$287,90772%
Speaking & faculty fees$45,95511%
Grants$2,0000%
Travel & lodging$35,7309%
Food & beverage$18,1475%
Education$10,9163%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
EMD Serono, Inc.	100	$78,588
Genentech USA, Inc.	67	$58,675
Bristol Myers Squibb	52	$56,242
Sanofi	41	$53,156
F. Hoffmann-la Roche AG	17	$32,120
Merck Kgaa	6	$22,056
Genentech, Inc.	36	$18,614
Merck Healthcare Kgaa	5	$16,314
Novartis	49	$15,977
E.r. Squibb & Sons, L.L.C.	6	$15,255
Novartis Pharma AG	3	$11,618
Amgen(2 entities)	24	$11,489
TG Therapeutics, Inc.	27	$8,421
Biogen	11	$1,908
AstraZeneca	3	$177
Acorda Therapeutics, Inc	2	$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OCREVUS$77,203
Ozanimod$35,256
ZEPOSIA$29,944
GILENYA$11,740
UPLIZNA$10,971
Evobrutinib$9,730
KESIMPTA$7,129
ARZERRA$5,500
BRIUMVI$4,630
Mavenclad$3,705
Enspryng$2,411
MAYZENT$238
ULTOMIRIS$120
Ocrevus Zunovo$108

How this compares

$400,654 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024

$10,588

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dalfampridine ErDalfampridine	28	$23,515
Baclofen	36	$846
Duloxetine Hcl	39	$727
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	20	$669
Gabapentin	16	$382
Tizanidine Hcl	27	$208
Clonazepam	17	$202
Pregabalin	16	$83
Trazodone Hcl	13	$32

Paid to pharmacies, not to this prescriber.

Other neurology in Houston

William OndoHouston$1.4M
Pankaj SatijaHouston$1.1M
Annette HowardHouston$826K
Randolph EvansHouston$493K
Mazen DimachkieHouston$388K
Zsila SadighiHouston$361K
Joseph JankovicHouston$323K
Raja MehannaHouston$300K
Eddie PattonHouston$299K
Nicolas NammourHouston$246K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →